Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ursodeoxycholic acid (UDCA) may modify the risk of inflammatory bowel disease (IBD)-associated colorectal cancer. We performed a systematic review and meta-analysis of studies evaluating the effect of UDCA on the risk of IBD-associated colorectal neoplasia (CRN) (defined as colorectal cancer and/or dysplasia) in patients with primary sclerosing cholangitis with concomitant IBD (PSC-IBD). METHODS: We conducted a systematic search of Medline, Embase, and Web of Science and manually reviewed the literature. Studies were included if they: (1) evaluated exposure to UDCA in patients with PSC-IBD, (2) reported IBD-associated CRN as outcome, and (3) reported relative risks or odds ratios (ORs) or provided data for their calculation. Summary OR estimates with 95% confidence intervals (CIs) were calculated using the random-effects model. RESULTS: Eight studies (5 observational, 3 randomized controlled trials) reporting 177 cases of CRN in 763 patients with PSC-IBD were included in the analysis. Overall, meta-analysis showed no significant protective association between UDCA use and CRN (OR, 0.81; 95% CI, 0.41-1.61). However, there was a significant chemopreventive effect on the risk of advanced CRN (colorectal cancer and/or high-grade dysplasia) (OR, 0.35; 95% CI, 0.17-0.73). In a subgroup analysis, low-dose UDCA use (8-15 mg/kg/d) was associated with significant risk reduction of CRN (OR, 0.19; 95% CI, 0.08-0.49). CONCLUSIONS: UDCA, particularly at low doses, may reduce the risk of advanced CRN in patients with PSC-IBD. However, results should be interpreted with caution, given limited reporting of cancer-related outcomes, primarily from tertiary care centers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although our data suggest that LCA is a risk factor for liver cancer, UDCA has been previously considered to be protective against colon cancer (39, 40).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [40]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“50% were suggestive of substantial heterogeneity.(28) Because of the small number of published studies, a formal statistical analysis of funnel plot asymmetry for assessment of publication bias was not used.”
BackgroundMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293 · cited 1×
“C olorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related mortality, worldwide.(1) Patients with inflammatory bowel disease (IBD), particularly those with long-standing extensive ulcerative colitis have a 2- to 5-fold increase in risk of CRC compared with the expected inci…”
BackgroundMeta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“Because of the small number of published studies, a formal statistical analysis of funnel plot asymmetry for assessment of publication bias was not used.(29) All P-values were 2 tailed.”
BackgroundRiddell, R. H., Goldman, H., Ransohoff, D. F., Appelman, H. D., Fenoglio, C. M., Haggitt, R. C., hren, C., Correa, P., Hamilton, S. R., Morson, B. C., et al. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80175-0 · Cited by 1,862
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J., Kliewer, E. V., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<785::aid-cncr1065>3.0.co;2-r · Cited by 1,179
Intestinal Inflammation and Cancer
Ullman, T. A., & Itzkowitz, S. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.057 · Cited by 1,119 · cited 1×
“Although most cases of sporadic CRC arise in dysplastic adenomas, following a well-recognized adenoma–carcinoma sequence,(7) IBD-associated CRC follows a different sequence of genetic alterations than sporadic CRC and is related to chronic inflammation-induced genomic instability with field cancerization changes.(8,9)…”
BackgroundJess, T., Rungoe, C., & Peyrin–Biroulet, L. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.010 · Cited by 958
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623 · cited 1×
“This risk increases 5- to 9fold further in patients with concomitant primary sclerosing cholangitis (PSC).(5,6) Although most cases of sporadic CRC arise in dysplastic adenomas, following a well-recognized adenoma–carcinoma sequence,(7) IBD-associated CRC follows a different sequence of genetic alterations than sporad…”
BackgroundUrsodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562 · cited 7×
“The effects may be more apparent with use of low-dose UDCA at doses of 8 to 15 mg/kg/d which was associated with an 82% reduction in the risk of all CRN in patients with PSC-IBD.”
BackgroundSelf-citationDecreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 Years
Jess, T., Simonsen, J., Jørgensen, K. T., Pedersen, B. V., Nielsen, N. M., & Frisch, M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.016 · Cited by 532 · cited 1×
“This risk increases 5- to 9fold further in patients with concomitant primary sclerosing cholangitis (PSC).(5,6) Although most cases of sporadic CRC arise in dysplastic adenomas, following a well-recognized adenoma–carcinoma sequence,(7) IBD-associated CRC follows a different sequence of genetic alterations than sporad…”
BackgroundTung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., & Brentnall, T. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00008 · Cited by 469 · cited 7×
“The effects may be more apparent with use of low-dose UDCA at doses of 8 to 15 mg/kg/d which was associated with an 82% reduction in the risk of all CRN in patients with PSC-IBD.”
BackgroundInfluentialMarchesa, P., Lashner, B. A., Lavery, I. C., Milsom, J. W., Hull, T. L., Strong, S. A., Church, J. M., Navarro, G., & Fazio, V. W. (1997) · PubMed · Cited by 329
Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.156 · Cited by 268
Self-citationKornfeld, D., Ekbom, A., & Ihre, T. (1997) · Gut · doi:10.1136/gut.41.4.522 · Cited by 251
Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence
Alberts, D. S., Martínez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., Guillen, J., Krutzsch, M., Batta, A. K., Salen, G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji144 · Cited by 247 · cited 1×
“, at the point that high-grade dysplastic changes develop in the colorectal mucosa.(41) However, this needs to be interpreted with caution because HGD was reported in a limited number of studies.”
BackgroundIncreased serum deoxycholic acid levels in men with colorectal adenomas
Bayerdörffer, E., Mannes, G. A., Richter, W. O., Ochsenkühn, T., Wiebecke, B., Köpcke, W., & Paumgartner, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90846-5 · Cited by 234 · cited 1×
“Clinical studies have shown that patients with IBD-associated and sporadic CRN have elevated fecal concentrations of secondary bile acids.(11,46) Administration of UDCA decreases fecal levels of deoxycholic acid in animal models, suggesting that alteration of the colonic bile acid milieu might be a mechanism for its c…”
BackgroundDl, E., Holubec, H., Wali, R. K., Jolley, C. S., BISSONNETTE, M., Bhattacharyya, A. K., Roy, H. K., Khare, S., & Brasitus, T. A. (1994) · PubMed · Cited by 209
Martinez, J. D., Stratagoules, E. D., LaRue, J. M., Powell, A. A., Gause, P. R., Craven, M. T., Payne, C. M., Powell, M. B., Gerner, E. W., & Earnest, D. L. (1998) · Nutrition and Cancer · doi:10.1080/01635589809514689 · Cited by 205
Seki, T., Wakabayashi, M., Nakagawa, T., Imamura, M., Tamai, T., Nishimura, A., Yamashiki, N., Okamura, A., & Inoue, K. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990415)85:8<1694::aid-cncr8>3.0.co;2-3 · Cited by 188
Leedham, S. J., Graham, T. A., Oukrif, D., McDonald, S. A. C., Rodriguez–Justo, M., Harrison, R. F., Shepherd, N. A., Novelli, M. R., Jankowski, J. A. Z., & Wright, N. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.086 · Cited by 185 · cited 1×
“Although most cases of sporadic CRC arise in dysplastic adenomas, following a well-recognized adenoma–carcinoma sequence,(7) IBD-associated CRC follows a different sequence of genetic alterations than sporadic CRC and is related to chronic inflammation-induced genomic instability with field cancerization changes.(8,9)…”
BackgroundUrsodeoxycholic Acid Protects Hepatocytes against Oxidative Injury via Induction of Antioxidants
Mitsuyoshi, H., Nakashima, T., Sumida, Y., Yoh, T., Nakajima, Y., Ishikawa, H., Inaba, K., Sakamoto, Y., Okanoue, T., & Kashima, K. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1403 · Cited by 169 · cited 1×
“It may also act as an antioxidant through stabilization of the mitochondrial membrane and prevention of free radical–mediated DNA damage.(51) Clinical observations have identified a dose–effect relationship between UDCA and therapeutic outcomes in human studies.”
BackgroundMore right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis
Claessen, M. M. H., Lutgens, M. W. M. D., van Buuren, H. R., Oldenburg, B., Stokkers, P. C. F., van der Woude, C. J., Hommes, D. W., de Jong, D. J., Dijkstra, G., van Bodegraven, A. A., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20886 · Cited by 132
WOLF, J. M., RYBICKI, L. A., & LASHNER, B. A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02650.x · Cited by 130 · cited 7×
“On restricting analysis to only CRC as outcome, we did not observe a chemopreventive effect of UDCA.”
MethodResultInfluentialEpidemiology and Risk Factors for Colorectal Dysplasia and Cancer in Ulcerative Colitis
Loftus, E. V. (2006) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2006.07.005 · Cited by 129
Self-citationQiao, D., Chen, W., Stratagoules, E. D., & Martinez, J. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908890199 · Cited by 120
Sinakos, E., Marschall, H.-U., Kowdley, K. V., Befeler, A., Keach, J., & Lindor, K. (2010) · Hepatology · doi:10.1002/hep.23631 · Cited by 119
Serfaty, L., De Leusse, A., Rosmorduc, O., Desaint, B., Flejou, J.-F., Chazouilleres, O., Poupon, R. E., & Poupon, R. (2003) · Hepatology · doi:10.1053/jhep.2003.50311 · Cited by 117
Sokol, H., Cosnes, J., Chazouilleres, O., Beaugerie, L., Tiret, E., Poupon, R., & Seksik, P. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3497 · Cited by 97
Wali, R. K., Frawley, B. P., Hartmann, S., Roy, H. K., Khare, S., Scaglione-Sewell, B., Earnest, D. L., Sitrin, M. D., Brasitus, T. A., & Bissonnette, M. (1995) · PubMed · Cited by 89
Wali, R. K., Khare, S., Tretiakova, M., Cohen, G., Nguyễn, L., Hart, J. A. L., Wang, J., Wen, M., Ramaswamy, A., Joseph, L. J., et al. (2002) · PubMed · Cited by 89
FAECAL BILE ACIDS, DYSPLASIA, AND CARCINOMA IN ULCERATIVE COLITIS
Lewin, M. R., Clark, C. G., Hill, M. J., Lennard‐Jones, J. E., & Melville, D. M. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91459-0 · Cited by 86
Lindström, L., Boberg, K. M., Wikman, O., Friis‐Liby, I., Hultcrantz, R., Prytz, H., Sandberg‐Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04966.x · Cited by 84 · cited 2×
“Specifically, doses between 8 and 15 mg/kg/d were associated with a significant reduction in the risk of CRN in 2 studies,(19,20) whereas doses between 15 and 30 mg/kg/d did not modify the risk of CRN in 3 studies.(22,31,33) For 2 of the other studies, only the median dose of UDCA was reported, and thus, a formal subg…”
BackgroundRudolph, G., Gotthardt, D. N., Kloeters-Plachky, P., Rost, D., Kulaksiz, H., & Stiehl, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.030 · Cited by 74
Ikegami, T., Matsuzaki, Y., Shoda, J., Kano, M., Hirabayashi, N., & Tanaka, N. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00248-1 · Cited by 69
Sjöqvist, U., Tribukait, B., Öst, Å., Einarsson, C., Oxelmark, L., & Löfberg, R. (2004) · PubMed · Cited by 62
BATTA, A. K., Salen, G., Holubec, H., Brasitus, T. A., Alberts, D. S., & Earnest, D. L. (1998) · PubMed · Cited by 61
Braden, B., Halliday, J., Aryasingha, S., Sharifi, Y., Checchin, D., Warren, B. F., Kitiyakara, T., Travis, S. P. L., & Chapman, R. W. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.10.020 · Cited by 60 · cited 2×
“Specifically, doses between 8 and 15 mg/kg/d were associated with a significant reduction in the risk of CRN in 2 studies,(19,20) whereas doses between 15 and 30 mg/kg/d did not modify the risk of CRN in 3 studies.(22,31,33) For 2 of the other studies, only the median dose of UDCA was reported, and thus, a formal subg…”
BackgroundKhare, S., Cerda, S., Wali, R. K., von Lintig, F. C., Tretiakova, M., Joseph, L. J., Stoiber, D., Cohen, G., Nimmagadda, K., Hart, J. A. L., et al. (2003) · PubMed · Cited by 59
Rigas, B., Tsioulias, G. J., Allan, C. H., Wali, R. K., & Brasitus, T. A. (1994) · PubMed Central · Cited by 46
Prevention of N‐Methylnitrosourea‐induced Colon Tumorigenesis by Ursodeoxycholic Acid in F344 Rats
Narisawa, T., Fukaura, Y., Terada, K., & Sekiguchi, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00489.x · Cited by 46
Navaneethan, U., Kochhar, G. S., Venkatesh, P. G. K., Lewis, B. L., Lashner, B. A., Remzi, F. H., Shen, B., & Kiran, R. P. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2012.01.015 · Cited by 43 · cited 6×
“On restricting analysis to only CRC as outcome, we did not observe a chemopreventive effect of UDCA.”
MethodResultInfluentialThompson, P. A., Wertheim, B. C., Roe, D. J., Ashbeck, E. L., Jacobs, E. T., Lance, P., Martínez, M. E., & Alberts, D. S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0234 · Cited by 38
Narisawa, T., Fukaura, Y., Terada, K., & Sekiguchi, H. (1999) · PubMed · Cited by 32
Ashraf, I., Choudhary, A., Arif, M., Matteson, M., Hammad, H. T., Puli, S. R., & Bechtold, M. L. (2012) · Indian Journal of Gastroenterology · doi:10.1007/s12664-012-0175-3 · Cited by 26 · cited 1×
“In their study, Ashraf et al included only 4 cohort studies, and they did not study the effect of low and high dose UDCA, separately.(45) Several investigations have demonstrated a chemopreventive”
BackgroundWertheim, B. C., Smith, J. W., Fang, C., Alberts, D. S., Lance, P., & Thompson, P. A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0320 · Cited by 24 · cited 1×
“UDCA efficacy for sporadic adenoma prevention may be modified by genetic variation in CYP7A1, the rate-limiting cholesterol 7a-hydroxylase enzyme that catalyzes the initial step in hepatic bile acid synthesis.(55) Thompson et al(56) also reported a significant influence of sex on the effects of UDCA in a phase III ran…”
BackgroundRudolph, G. G., Gotthardt, D. N., Kloeters-Plachky, P., Kulaksiz, H., Schirmacher, P., & Stiehl, A. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1763-2 · Cited by 18
Larson, M. V. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04830-x · Cited by 3
Ullman, T. A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)01549-1 · Cited by 2 · cited 1×
“One study was published only in the abstract form.(34) Four studies were excluded since relative risk or OR could not be calculated.”
Background
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
“Finally, although mortality in pediatric UC has become rare, a retrospective case collection across Europe over 6 years reported 19 deaths in children with UC mainly due to infections and cancer (1 case of colorectal cancer [CRC]), including 1 with toxic megacolon (10).”
BackgroundInfluentialRole of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Metadata
- Authors
- Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07
- Volume
- 19
- Issue
- 8
- Pages
- 1631-1638
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2316014275
- Cited by
- 94
- References
- 56
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- ursodeoxycholic acid, primary sclerosing cholangitis
- MeSH terms
- Cholagogues and Choleretics, Humans, Prognosis, Ursodeoxycholic Acid, Colorectal Neoplasms, Meta-Analysis as Topic, Cholangitis, Sclerosing, Inflammatory Bowel Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.